Results 161 to 170 of about 12,689 (172)

Thirty-day hospital readmission and its determinants among patients with severe community-acquired pneumonia: a prospective cross-sectional study in Northwest Ethiopia. [PDF]

BMC Infect Dis
Tekle MT, Jara AG, Sema FD.
europepmc   +1 more source

İslam açısından musıki ve semâ

, 1991
Uludağ, Süleyman
core  

Testing DAT1 and DRD4 Genes in Attention Deficit Hyperactivity Disorder Using a Wide Spectrum of Neurocognitive Batteries. [PDF]

Int J Dev Neurosci
Ünsel-Bolat G, Bolat H, Yıldırım S, Özgül S, Tahıllıoğlu A, Yazıcı KU, Bacanlı A, Parıltay E, Aygüneş-Jafari D, Kosova B, Rohde LA, Akın H, Ercan ES.   +12 more
europepmc   +1 more source

“ ‘İkiz Ruhlar’ın Konuşma Dili Semâ”

, 2007
ÇETİNKAYA, Bayram Ali
core  

Severe malaria treatment with rectal artesunate and artemisinin-based combination therapy in remote settings: an effectiveness-implementation hybrid type 3 study protocol (SEMA ReACT). [PDF]

Malar J
Hachizovu S, Manyando C, Nambozi M, Khondowe S, Hamainza B, Mukumbuta D, Rietveld H, Mukomena Sompwe E, Kikunda G, Muhindo-Mavoko H, Luzolo Khote F, Kanyamukenge D, Bastiaens H, Kakudji A, Maseko T, Makenga G, Baraka V, Mutombo A, Duparc S, Van Geertruyden JP.   +19 more
europepmc   +1 more source

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management. [PDF]

Mol Metab
Carlson TL, Fineman M, Kernodle S, Hutch CR, Bryant C, Colbert K, Seeley RJ, Nimgaonkar A.   +7 more
europepmc   +1 more source

A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity. [PDF]

Metabolism
Ashlaw EF, Elfers CT, Chichura KS, Miranda IC, McGivney A, Chepurny OG, Holz GG, Mullins G, den Hartigh LJ, Liu Y, Roth CL, Doyle RP.   +11 more
europepmc   +1 more source

“Mevlevilikte Aşkın Estetik Tezahürü Semâ ve Musiki"

, 2016
Turan, Namık Sinan
core  

Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. [PDF]

Eur Heart J
Park B, Dennis F, He AZ, Krishnaraj A, Bakbak E, Dennis CJ, Pan Y, Misner E, Thayanithy V, Lambotharan B, Lambotharan V, Lambotharan A, Mazer CD, Quan A, Teoh H, Hess DA, Verma S.   +16 more
europepmc   +1 more source